A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants

Journal of Tropical Pediatrics

Volumn 58, Issue 1, 2012, Pages 25-30

  Wahab mohamed, Walid Abdel ^a,b   Ismail, Mahmoud ^c,d  

^a MINIA UNIVERSITY   (Egypt)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

^c ZAGAZIG UNIVERSITY   (Egypt)

^d KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Amphotericin B; Caspofungin; Invasive candidiasis; Neonates

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN;

ARTICLE; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPOTENSION; INFANT; MALE; NEPHROTOXICITY; PHLEBITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TREATMENT RESPONSE; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 84856380878     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmr025     Document Type: Article

References (22)

1. Carla O, Roberto A, Luis P, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis 2004;23:1093-7.
2. Stronati M, Decembrino L. Neonatal invasive candidiasis. Minerva Pediatr 2006;58:537-49.
3. Del Palacio A, Villar J, Alhambra A. Epidemiology of invasive candidiasis in pediatric and adult populations. Rev Iberoam Micol 2009;26:2-7.
4. Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev Anti Infect Ther 2010;8:127-35.
5. Mahieu LM, Van Gasse N, Wildemeersch D, et al. Number of sites of perinatal Candida colonization and neutropenia are associated with nosocomial candidemia in the neonatal intensive care unit patient. Pediatr Crit Care Med 2010;11:240-5.
6. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010;26:1761-8.
7. Das S, Shivaprakash MR, Chakrabarti A. New antifungal agents in pediatric practice. Indian Pediatr 2009;46: 225-31.
8. Theoklis Z, Thomas L, Andreas H, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis 2009;28:1132-5.
9. Manzoni P, Rizzollo S, Franco C, et al. Role of echinocandins in the management of fungal infections in neonates. J Matern Fetal Neonatal Med 2010;23:49-52.
10. Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
11. Benjamin DK, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors and clinical judgment. Pediatrics 2010;126:865-73.
12. Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010;26:1769-78.
13. Almirante B, Rodri{dotless}́guez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007;9:311-21.
14. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
15. Grover ND. Echinocandins: a ray of hope in antifungal drug therapy. Indian J Pharmacol 2010;42:9-11.
16. Maertens J, Madero L, Reilly A, et al. A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic pediatric patients. Pediatr Infect Dis 2010;29:415-20.
17. Neely M, Jafri H, Seibel N, et al. The pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009;53:1450-6.
18. Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75.
19. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45.
20. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-84.
21. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41.
22. Gullo A. Invasive fungal infections: the challenge continues. Drugs 2009;69:65-73.